跳至主要内容
临床试验/NCT03635359
NCT03635359Unknown不适用

Fluidic Automated Screening for Trisomy Study I

BioCeryx6 个研究点 分布在 6 个国家目标入组 2,000 人开始时间: 2017年7月15日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
2,000
试验地点
6
主要终点
Comparison of blood test to fetal karyotype

研究概览

简要总结

The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Subject is at least 18 years old and can provide informed consent;
  • Subject has a viable singleton or twin pregnancy;
  • Subject is confirmed to be at least 10 weeks, 0 days gestation at the time of the study blood draw;
  • Subject is planning to undergo chorionic villus sampling and/or amniocentesis for the purpose of genetic analysis of the fetus because of a suspected fetal chromosomal anomaly based on cell-free DNA test results, standard serum screening result, or fetal ultrasound abnormality.
  • OR the subject has already undergone chorionic villus sampling and/or amniocentesis and is known to have a fetus with a chromosomal abnormality confirmed by genetic analysis.

排除标准

  • Subject (the mother) has known aneuploidy;
  • Subject is pregnant with more than two fetuses or has had sonographic evidence of three or more gestational sacs at any time during pregnancy;
  • Subject has a fetal demise (including natural or elective reduction) identified prior to consent;
  • Subject has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

结局指标

主要结局

Comparison of blood test to fetal karyotype

时间窗: 21 months

Maternal plasma cell-free DNA will be analyzed to determine copy number of specific chromosomes and compared to the fetal karyotype as obtained through invasive diagnostic testing of the fetus.

次要结局

未报告次要终点

研究者

发起方
BioCeryx
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验